D. Pectasides

Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms.

Nigel Courtenay-Luck, Agamemnon A. Epenetos, Richard E. Moore et al. · PubMed · 1986 · 209 citations

Pharmacy, Immunology, Oncology +17

Gemcitabine and oxaliplatin (GEMOX) in patients withcisplatin-refractory germ cell tumors: a phase II study

D. Pectasides, Melina Pectasides, Dimitrios Farmakis et al. · Annals of Oncology · 2004 · 102 citations

Medicine, Oncology, Chemotherapy +9

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

George Fountzilas, Dimosthenis Skarlos, Urania Dafni et al. · Annals of Oncology · 2005 · 100 citations · Full text

Medicine, Oncology, Pharmacology +12

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Comparison of docetaxel and docetaxel–irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial

D. Pectasides, Melina Pectasides, Dimitrios Farmakis et al. · Annals of Oncology · 2005 · 85 citations · Full text

Medicine, Oncology, Pharmacology +10